Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02680184 |
|
Recruitment Status :
Completed
First Posted : February 11, 2016
Last Update Posted : January 11, 2023
|
Sponsor:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Regeneron Pharmaceuticals
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | December 6, 2022 |
| Actual Study Completion Date : | December 6, 2022 |